MAPT and Alzheimer disease: Relative to their 3xTg and M83 counterparts, DLB-AD mice display significantly higher phosphorylated αsyn levels at 6 and 12 months, increased Aβ and phosphorylated tau levels by 12 months, and accelerated cognitive decline.